Nykode Therapeutics ASA
XMUN:5VB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
N
|
Nykode Therapeutics ASA
XMUN:5VB
|
NO |
Nykode Therapeutics ASA
Nykode Therapeutics is a biotechnology company that develops DNA-based vaccines and immunotherapy candidates for cancer and infectious diseases. Its main work is to design vaccine programs that train the immune system to recognize specific targets, then move those candidates through research and clinical testing. The company is not a drug seller in the usual sense; it is building a pipeline of experimental medicines around its core vaccine technology. The company’s customers are mainly large pharmaceutical partners, research collaborators, and eventually patients if its products win regulatory approval. Today it makes money mostly through collaboration and licensing deals, research funding from partners, and other biotech-style partnership payments tied to its technology and development programs. If its candidates succeed, future revenue would also come from product sales or royalties. What makes Nykode different is that it sits earlier in the drug value chain than a traditional drugmaker. Instead of manufacturing a broad portfolio of approved medicines, it focuses on creating a platform that can be used to build multiple vaccine candidates from the same underlying technology. That gives it a business model centered on scientific development, partnerships, and long timelines to reach the market.
Nykode Therapeutics is a biotechnology company that develops DNA-based vaccines and immunotherapy candidates for cancer and infectious diseases. Its main work is to design vaccine programs that train the immune system to recognize specific targets, then move those candidates through research and clinical testing. The company is not a drug seller in the usual sense; it is building a pipeline of experimental medicines around its core vaccine technology.
The company’s customers are mainly large pharmaceutical partners, research collaborators, and eventually patients if its products win regulatory approval. Today it makes money mostly through collaboration and licensing deals, research funding from partners, and other biotech-style partnership payments tied to its technology and development programs. If its candidates succeed, future revenue would also come from product sales or royalties.
What makes Nykode different is that it sits earlier in the drug value chain than a traditional drugmaker. Instead of manufacturing a broad portfolio of approved medicines, it focuses on creating a platform that can be used to build multiple vaccine candidates from the same underlying technology. That gives it a business model centered on scientific development, partnerships, and long timelines to reach the market.
Abi-suva progress: Nykode said its lead cancer program moved from trial setup into execution, with the first patient dosed in the randomized Phase II Abili-T study and an interim readout still expected in 2027.
Early signal: The company highlighted interim C-03 Part 1 data showing a 39% objective response rate in 13 patients, versus about 19% for KEYTRUDA alone, and said the immunogenicity data further strengthened its confidence.
Cash runway: Nykode ended the quarter with $51.3 million of cash and said its runway extends into 2028, with a possible extension into 2029 if the pending tax case is resolved positively.
VB10.NEO focus: Management said individualized neoantigen therapy remains a strategic priority, but the company does not plan to run a VB10.NEO trial on its own right now and is positioning the asset for partnering.
Autoimmune platform: The autoimmune program showed more human translational data, and management said a Board strategic review in August will help तयermine how to advance it next year.
AI use: Nykode described AI and machine learning as a long-standing core part of its neoantigen work and said it is now using those tools more broadly across the company.
